Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests will soon surpass 90 million lives as an in-network benefit for patients.…